Tesamorelin Half-Life in 2026: What the Data Actually Shows
Tesamorelin Half-Life in 2026: What the Data Actually Shows
Tesamorelin’s elimination half-life isn’t one fixed number — FDA data shows it ranges from roughly 8 minutes to 38 minutes depending on the formulation (Egrifta, Egrifta SV, Egrifta WR), dose, route of administration, and whether the subject is healthy or HIV-infected. This short half-life is precisely why tesamorelin is dosed once daily rather than intermittently — it works by triggering a pulse of GH release, not by maintaining constant blood levels.
Table of Contents
- Why Tesamorelin’s Half-Life Isn’t a Single Number
- Tesamorelin Half-Life FDA Label Data
- Tesamorelin Pharmacokinetics in Healthy Subjects
- Tesamorelin Half-Life in HIV-Infected Patients
- Egrifta SV Half-Life
- Egrifta WR Half-Life
- Tesamorelin Peak Plasma Concentration
- Tesamorelin Once-Daily Dosing Rationale
- Tesamorelin Half-Life vs Growth Hormone-Releasing Hormone
- Tracking Tesamorelin Without the Guesswork
Why Tesamorelin’s Half-Life Isn’t a Single Number
Search
Frequently Asked Questions
What is the half-life of tesamorelin?
It depends on the study. FDA labeling reports a mean elimination half-life of about 8 minutes for Egrifta and Egrifta SV after a single dose in healthy subjects, 11 minutes for Egrifta WR, and up to 26–38 minutes in earlier repeated-dose and HIV-infected patient studies.
Why does tesamorelin’s half-life vary so much between sources?
Different FDA-reviewed studies used different formulations, doses, routes of administration, and patient populations. Single-dose data in healthy subjects tends to show shorter half-lives than repeated-dose data in HIV-infected patients.
How long does tesamorelin stay in your system?
Given a half-life of roughly 8 to 38 minutes, tesamorelin is largely cleared from plasma within a few hours of injection, which is why it’s dosed once daily rather than relied upon for sustained blood levels.
Does a short half-life mean tesamorelin is less effective?
No — tesamorelin is designed to trigger a brief, pulsatile release of growth hormone similar to the body’s natural GHRH signaling, so a short half-life is part of how it’s meant to work, not a flaw.
Is Egrifta WR’s half-life different from older Egrifta formulations?
Yes, slightly. FDA data shows Egrifta WR (the ready-to-use 11.6 mg/vial formulation) has a mean half-life of about 11 minutes after a single dose, compared to about 8 minutes for the older Egrifta and Egrifta SV formulations.